glp-1 drug companies FDA says that the shortage is over top glp 1 drug companies

doi: 10.1053/j.gastro.2022.08.045

What is a GLP-1

Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity

The other factor is that patents for GLP-1s are set to expire in large markets like China, India, Brazil, Canada and Turkey, where 40% of the global population (and roughly 33% of adults considered obese) live

Nausea, vomiting, and diarrhea are the most frequently reported adverse events, typically mild to moderate in severity and decreasing over time

[DOI] [PMC free article] [PubMed] [Google Scholar] 15.Faurschou A, Knop FK, Thyssen JP, Zachariae C, Skov L, Vilsbll T